Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Fresolimumab vs Placebo in Steroid-Resistant Primary FSGS
2012-002365-35Phase 2Completed
- Sponsor
- Sanofi
- Start
- Mar 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in focal segmental glomerulosclerosis (FSGS) comparing Fresolimumab with Placebo (2 arms). Primary endpoint: Partial or complete remission of proteinuria (Up/c ratio). Started Mar 2013; status: completed.
02
Drugs
fresolimumab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2012-002365-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002365-35.